{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-343477","form_type":"8-K","ticker":"KLRS","cik":"0001754068","company_name":"Kalaris Therapeutics, Inc.","filed_at":"2026-08-11T12:05:28+00:00","discovered_at":"2026-08-11T12:10:07.150148+00:00","generated_at":"2026-08-11T12:10:41.490720+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Kalaris Q2 2026 net loss $11.5M; cash $93.5M funds operations into Q4 2027","bullets":["Net loss $11.5M for Q2 2026 vs $11.4M in Q2 2025; R&D expense $9.0M (up from $8.4M).","Cash, equivalents and marketable securities $93.5M as of June 30, 2026, down from $118.0M at Dec 31, 2025.","Phase 1b/2 TH103 study dosing ongoing; preliminary data expected 1H 2027; Phase 3 start on track for year-end 2027.","Expanded Phase 1a data released, reinforcing BCVA, OCT, pharmacokinetic and time-to-retreatment findings.","Leadership additions: Liisa Bayko as CFO (from Evercore ISI) and Laurie Keating to Board of Directors."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-343477","json":"https://secwatch.observer/filing/0001193125-26-343477.json","markdown":"https://secwatch.observer/filing/0001193125-26-343477.md","text":"https://secwatch.observer/filing/0001193125-26-343477.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1754068/000119312526343477/0001193125-26-343477-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1754068/000119312526343477/d114296d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-11T12:10:41.490720+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}